Diabetic Retinopathy - Competitive Landscape, Pipeline and Market Analysis, 2017
This report can be delivered to the clients within 24 Hours
DelveInsight’s Diabetic Retinopathy - Competitive Landscape, Pipeline and Market Analysis, 2017 report provides an overview of the epidemiology trends of Diabetic Retinopathy in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes the historical and forecasted epidemiology data for Diabetic Retinopathy prevalent or incident cases segmented by age, sex and subpopulations. The report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Diabetic Retinopathy. Further, therapeutic assessment of pipeline products by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates are covered in this report. A comprehensive review of the market trends, drivers, barriers, key company profiles including its business and product developments are also detailed here. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight’s team of industry experts.
KEY COVERAGE AND BENEFITS
DelveInsight’s Diabetic Retinopathy - Competitive Landscape, Pipeline and Market Analysis, 2017 report provides an overview of the epidemiology trends of Diabetic Retinopathy in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes the historical and forecasted epidemiology data for Diabetic Retinopathy prevalent or incident cases segmented by age, sex and subpopulations. The report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Diabetic Retinopathy. Further, therapeutic assessment of pipeline products by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates are covered in this report. A comprehensive review of the market trends, drivers, barriers, key company profiles including its business and product developments are also detailed here. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight’s team of industry experts.
KEY COVERAGE AND BENEFITS
- The report will help in developing business strategies by understanding the trends shaping and driving the global Diabetic Retinopathy market
- Identifying prevalent patient populations as well as risk factors in the global Diabetic retinopathy market will help to improve product design, pricing, and launch plans
- To understand the current pipeline scenario of different companies so as to make the research activity more robust and competitive
- To understand the future market competition in the global Diabetic Retinopathy market and Insightful review of the key market drivers and barriers
- The report also covers the detailed global historical and forecasted Diabetic Retinopathy market covering United States, European Union 5 (EU5 - Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023
Report Introduction
Diabetic Retinopathy (DR) Market Overview at a Glance
Global Market Size of DR in 2016
Global Market Size of DR in 2023
Diabetic Retinopathy: Overview
Stages
Symptoms
Types
Pathophysiology
Etiology
Risk Factors
Disease Burden
Unmet Needs
Epidemiology of Diabetic Retinopathy in 7MM (2013-2023)
United States
Sex Specific Prevalence of Diabetes Retinopathy in US
Age-Specific Prevalence of Diabetes Retinopathy in US
Sub-type Prevalence of Diabetes Retinopathy in US
EU5
United Kingdom
Sex Specific Prevalence of Diabetes Retinopathy in UK
Age-Specific Prevalence of Diabetes Retinopathy in UK
Sub-type Prevalence of Diabetes Retinopathy in UK
France
Sex Specific Prevalence of Diabetes Retinopathy in France
Age-Specific Prevalence of Diabetes Retinopathy in France
Sub-type Prevalence of Diabetes Retinopathy in France
Italy
Sex Specific Prevalence of Diabetes Retinopathy in Italy
Age-Specific Prevalence of Diabetes Retinopathy in Italy
Sub-type Prevalence of Diabetes Retinopathy in Italy
Germany
Sex Specific Prevalence of Diabetes Retinopathy in Germany
Age-Specific Prevalence of Diabetes Retinopathy in Germany
Sub-type Prevalence of Diabetes Retinopathy in Germany
Spain
Sex Specific Prevalence of Diabetes Retinopathy in Spain
Age-Specific Prevalence of Diabetes Retinopathy in Spain
Sub-type Prevalence of Diabetes Retinopathy in Spain
Japan
Sex Specific Prevalence of Diabetes Retinopathy in Japan
Age-Specific Prevalence of Diabetes Retinopathy in Japan
Sub-type Prevalence of Diabetes Retinopathy in Japan
Treatment Algorithm
Global Diabetic Retinopathy: Country-Wise Market Analysis
Total Market Size of Diabetic Retinopathy (2013-2023)
United States
EU5
United Kingdom
Germany
France
Italy
Spain
Japan
Competitive Landscape
Marketed Drugs
EYLEA
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety & Efficacy
Side effects of EYLEA
Other Marketed Drug profiles in detailed report
Pipeline Therapeutics
An Overview of Pipeline Products for Diabetic Retinopathy and Diabetic Macular Edema
Comparative Analysis
Pipeline Therapeutics
Pipeline Therapeutics Overview
Late Stage Products (Filed and Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Drug Candidate Profile
Emixustat HCl: Acucela Inc.
Product Description
Research and Development
Other Development Activities (Deals and Partnership )
Other Pipeline Drug profiles in detailed report
Therapeutic Assessment
Assessment by Product Type
Assessment by Phase for Monotherapy
Assessment by Phase for Combination therapy
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Route of AdministrationAssessment by Stage and Route of Administration
Dormant Products
Discontinued Products
Analyst’s Insights
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Diabetic Retinopathy (DR) Market Overview at a Glance
Global Market Size of DR in 2016
Global Market Size of DR in 2023
Diabetic Retinopathy: Overview
Stages
Symptoms
Types
Pathophysiology
Etiology
Risk Factors
Disease Burden
Unmet Needs
Epidemiology of Diabetic Retinopathy in 7MM (2013-2023)
United States
Sex Specific Prevalence of Diabetes Retinopathy in US
Age-Specific Prevalence of Diabetes Retinopathy in US
Sub-type Prevalence of Diabetes Retinopathy in US
EU5
United Kingdom
Sex Specific Prevalence of Diabetes Retinopathy in UK
Age-Specific Prevalence of Diabetes Retinopathy in UK
Sub-type Prevalence of Diabetes Retinopathy in UK
France
Sex Specific Prevalence of Diabetes Retinopathy in France
Age-Specific Prevalence of Diabetes Retinopathy in France
Sub-type Prevalence of Diabetes Retinopathy in France
Italy
Sex Specific Prevalence of Diabetes Retinopathy in Italy
Age-Specific Prevalence of Diabetes Retinopathy in Italy
Sub-type Prevalence of Diabetes Retinopathy in Italy
Germany
Sex Specific Prevalence of Diabetes Retinopathy in Germany
Age-Specific Prevalence of Diabetes Retinopathy in Germany
Sub-type Prevalence of Diabetes Retinopathy in Germany
Spain
Sex Specific Prevalence of Diabetes Retinopathy in Spain
Age-Specific Prevalence of Diabetes Retinopathy in Spain
Sub-type Prevalence of Diabetes Retinopathy in Spain
Japan
Sex Specific Prevalence of Diabetes Retinopathy in Japan
Age-Specific Prevalence of Diabetes Retinopathy in Japan
Sub-type Prevalence of Diabetes Retinopathy in Japan
Treatment Algorithm
Global Diabetic Retinopathy: Country-Wise Market Analysis
Total Market Size of Diabetic Retinopathy (2013-2023)
United States
EU5
United Kingdom
Germany
France
Italy
Spain
Japan
Competitive Landscape
Marketed Drugs
EYLEA
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety & Efficacy
Side effects of EYLEA
Other Marketed Drug profiles in detailed report
Pipeline Therapeutics
An Overview of Pipeline Products for Diabetic Retinopathy and Diabetic Macular Edema
Comparative Analysis
Pipeline Therapeutics
Pipeline Therapeutics Overview
Late Stage Products (Filed and Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Drug Candidate Profile
Emixustat HCl: Acucela Inc.
Product Description
Research and Development
Other Development Activities (Deals and Partnership )
Other Pipeline Drug profiles in detailed report
Therapeutic Assessment
Assessment by Product Type
Assessment by Phase for Monotherapy
Assessment by Phase for Combination therapy
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Route of AdministrationAssessment by Stage and Route of Administration
Dormant Products
Discontinued Products
Analyst’s Insights
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
LIST OF TABLES
Table 1: Prevalent Population of Diabetic Retinopathy in United States (2013-2023)
Table 2: Sex Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Table 3: Age-Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Table 4: Sub-type Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Table 5: Prevalent Population of Diabetic Retinopathy in United Kingdom (2013-2023)
Table 6: Sex Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Table 7: Age-Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Table 8: Sub-type Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Table 9: Prevalent Population of Diabetic Retinopathy in France (2013-2023)
Table 10: Sex Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Table 11: Age-Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Table 12: Sub-type Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Table 13: Prevalent Population of Diabetic Retinopathy in Italy (2013-2023)
Table 14: Sex Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Table 15: Age-Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Table 16: Sub-type Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Table 17: Prevalent Population of Diabetic Retinopathy in Germany (2013-2023)
Table 18: Sex Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Table 19: Age-Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Table 20: Sub-type Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Table 21: Prevalent Population of Diabetic Retinopathy in Spain (2013-2023)
Table 22: Sex Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Table 23: Age-Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Table 24: Sub-type Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Table 25: Prevalent Population of Diabetic Retinopathy in Japan (2013-2023)
Table 26: Sex Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Table 27: Age-Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Table 28: Sub-type Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Table 29: Total Market size of Diabetic Retinopathy in USD Billion (2013-2023)
Table 30: United States Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 31: United Kingdom Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 32: Germany Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 33: France Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 34: Italy Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 35: Spain Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 36: Japan Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 37: Pipeline Therapeutics for Diabetic Retinopathy Drugs, 2017
Table 38: Comparative Table for Diabetic Retinopathy Drugs, 2017
Table 39: Late Stage Products (Filed and Phase III), 2017
Table 40: Mid Stage Products (Phase II), 2017
Table 41: Early Stage Products (Phase I), 2017
Table 42: Pre-Clinical and Discovery Products, 2017
Table 49: Therapeutic Assessment, 2017
Table 50: Dormant Products, 2017
Table 51: Discontinued Products, 2017
Table 1: Prevalent Population of Diabetic Retinopathy in United States (2013-2023)
Table 2: Sex Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Table 3: Age-Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Table 4: Sub-type Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Table 5: Prevalent Population of Diabetic Retinopathy in United Kingdom (2013-2023)
Table 6: Sex Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Table 7: Age-Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Table 8: Sub-type Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Table 9: Prevalent Population of Diabetic Retinopathy in France (2013-2023)
Table 10: Sex Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Table 11: Age-Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Table 12: Sub-type Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Table 13: Prevalent Population of Diabetic Retinopathy in Italy (2013-2023)
Table 14: Sex Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Table 15: Age-Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Table 16: Sub-type Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Table 17: Prevalent Population of Diabetic Retinopathy in Germany (2013-2023)
Table 18: Sex Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Table 19: Age-Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Table 20: Sub-type Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Table 21: Prevalent Population of Diabetic Retinopathy in Spain (2013-2023)
Table 22: Sex Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Table 23: Age-Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Table 24: Sub-type Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Table 25: Prevalent Population of Diabetic Retinopathy in Japan (2013-2023)
Table 26: Sex Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Table 27: Age-Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Table 28: Sub-type Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Table 29: Total Market size of Diabetic Retinopathy in USD Billion (2013-2023)
Table 30: United States Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 31: United Kingdom Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 32: Germany Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 33: France Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 34: Italy Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 35: Spain Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 36: Japan Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Table 37: Pipeline Therapeutics for Diabetic Retinopathy Drugs, 2017
Table 38: Comparative Table for Diabetic Retinopathy Drugs, 2017
Table 39: Late Stage Products (Filed and Phase III), 2017
Table 40: Mid Stage Products (Phase II), 2017
Table 41: Early Stage Products (Phase I), 2017
Table 42: Pre-Clinical and Discovery Products, 2017
Table 49: Therapeutic Assessment, 2017
Table 50: Dormant Products, 2017
Table 51: Discontinued Products, 2017
LIST OF FIGURES
Figure 1: Risk Factors of Diabetic Retinopathy
Figure 2: Prevalent Population of Diabetic Retinopathy in United States (2013-2023)
Figure 3: Sex Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Figure 4: Age-Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Figure 5: Sub-type Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Figure 6: Prevalent Population of Diabetes Retinopathy in United Kingdom (2013-2023)
Figure 7: Sex Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Figure 8: Age-Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Figure 9: Sub-type Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Figure 10: Prevalent Population of Diabetic Retinopathy in France (2013-2023)
Figure 11: Sex Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Figure 12: Age-Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Figure 13: Sub-type Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Figure 14: Prevalent Population of Diabetic Retinopathy in Italy (2013-2023)
Figure 15: Sex Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Figure 16: Age-Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Figure 17: Sub-type Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Figure 18: Prevalent Population of Diabetic Retinopathy in Germany (2013-2023)
Figure 19: Sex Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Figure 20: Age-Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Figure 21: Sub-type Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Figure 22: Prevalent Population of Diabetic Retinopathy Spain (2013-2023)
Figure 23: Sex Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Figure 24: Age-Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Figure 25: Sub-type Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Figure 26: Prevalent Population of Diabetic Retinopathy in Japan (2013-2023)
Figure 27: Sex Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Figure 28: Age-Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Figure 29: Sub-type Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Figure 30: Total Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 31: United States Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 32: United Kingdom Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 33: Germany Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 34: France Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 35: Italy Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 36: Spain Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 37: Japan Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 38: Marketed and Pipeline drugs for Diabetic Retinopathy, 2017
Figure 39: Vyndaqel Historical and forecasted Global Market Size in USD, Million (2016-2022)
Figure 40: Total Products for Diabetic Retinopathy, 2017
Figure 41: Late Stage Products (Filed and Phase III), 2017
Figure 42: Mid Stage Products (Phase II), 2017
Figure 43: Early Stage Products (Phase I), 2017
Figure 44: Pre-Clinical and Discovery Products, 2017
Figure 45: Patisiran Forecasted Sales in USD, Million (2018-2022)
Figure 46: Number of Monotherapy Products for Diabetic Retinopathy, 2017
Figure 47: Number of Combination Therapy Products for Diabetic Retinopathy, 2017
Figure 48: Percentage of pipeline drugs by Molecule Type (%), 2017
Figure 49: Assessment by Stage and Molecule Type, 2017
Figure 50: Pipeline Drugs by Route of Administration, 2017
Figure 51: Assessment by Stage and Route of Administration, 2017
Figure 52: Dormant Products, 2017
Figure 1: Risk Factors of Diabetic Retinopathy
Figure 2: Prevalent Population of Diabetic Retinopathy in United States (2013-2023)
Figure 3: Sex Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Figure 4: Age-Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Figure 5: Sub-type Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
Figure 6: Prevalent Population of Diabetes Retinopathy in United Kingdom (2013-2023)
Figure 7: Sex Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Figure 8: Age-Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Figure 9: Sub-type Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
Figure 10: Prevalent Population of Diabetic Retinopathy in France (2013-2023)
Figure 11: Sex Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Figure 12: Age-Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Figure 13: Sub-type Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
Figure 14: Prevalent Population of Diabetic Retinopathy in Italy (2013-2023)
Figure 15: Sex Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Figure 16: Age-Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Figure 17: Sub-type Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
Figure 18: Prevalent Population of Diabetic Retinopathy in Germany (2013-2023)
Figure 19: Sex Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Figure 20: Age-Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Figure 21: Sub-type Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
Figure 22: Prevalent Population of Diabetic Retinopathy Spain (2013-2023)
Figure 23: Sex Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Figure 24: Age-Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Figure 25: Sub-type Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
Figure 26: Prevalent Population of Diabetic Retinopathy in Japan (2013-2023)
Figure 27: Sex Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Figure 28: Age-Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Figure 29: Sub-type Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
Figure 30: Total Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 31: United States Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 32: United Kingdom Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 33: Germany Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 34: France Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 35: Italy Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 36: Spain Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 37: Japan Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
Figure 38: Marketed and Pipeline drugs for Diabetic Retinopathy, 2017
Figure 39: Vyndaqel Historical and forecasted Global Market Size in USD, Million (2016-2022)
Figure 40: Total Products for Diabetic Retinopathy, 2017
Figure 41: Late Stage Products (Filed and Phase III), 2017
Figure 42: Mid Stage Products (Phase II), 2017
Figure 43: Early Stage Products (Phase I), 2017
Figure 44: Pre-Clinical and Discovery Products, 2017
Figure 45: Patisiran Forecasted Sales in USD, Million (2018-2022)
Figure 46: Number of Monotherapy Products for Diabetic Retinopathy, 2017
Figure 47: Number of Combination Therapy Products for Diabetic Retinopathy, 2017
Figure 48: Percentage of pipeline drugs by Molecule Type (%), 2017
Figure 49: Assessment by Stage and Molecule Type, 2017
Figure 50: Pipeline Drugs by Route of Administration, 2017
Figure 51: Assessment by Stage and Route of Administration, 2017
Figure 52: Dormant Products, 2017
